Bristol Myers Squibb (CELG-RI) Total Debt Growth (5y) (2014 - 2026)
Bristol Myers Squibb (CELG-RI) Total Debt Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.63% |
| Mar 31, 2026 | 0.07% |
| Dec 31, 2025 | -2.30% |
| Sep 30, 2025 | 0.32% |
| Jun 30, 2025 | 1.05% |
| Mar 31, 2025 | -0.10% |
| Dec 31, 2024 | 1.95% |
| Sep 30, 2024 | 14.79% |
| Jun 30, 2024 | 17.31% |
| Mar 31, 2024 | 56.05% |
| Dec 31, 2023 | 37.75% |
| Sep 30, 2023 | 38.77% |
| Jun 30, 2023 | 38.52% |
| Mar 31, 2023 | 37.49% |
| Dec 31, 2022 | 39.44% |
| Sep 30, 2022 | 37.17% |
| Jun 30, 2022 | 38.62% |
| Mar 31, 2022 | 44.03% |
| Dec 31, 2021 | 46.03% |
| Sep 30, 2021 | 48.63% |